Explore the latest advances in RSV vaccine research, and what these developments mean for prevention and public health.

MSD has received the EC approval for Enflonsia, indicated to prevent RSV lower respiratory tract disease in newborns and infants during their initial RSV season.

Merck , known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIAtm (clesrovimab) for the prevention of respiratory syncytial virus ...

Eradivir Inc., a clinical-stage biotech company developing antibody-recruiting small molecules to treat disease, today ...

The average human has about 1.8 trillion immune cells. These cells patrol the body for bacteria, viruses, cancers, and other ...

Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory ...

As some Baltimore City leaders voice concern over the proposed budget and possible expansion of the Mayor's office, data shows other jurisdictions have smaller Taneytown Police Department seeks public ...

AI predicted that a forgotten breast cancer drug could be repurposed to treat many respiratory and gastrointestinal viruses, and subsequent animal tests suggests it may be right ...

Aging gradually erodes the body’s ability to maintain internal balance, in part due to the buildup of senescent cells that fuel inflammation and disease. New research explores how metabolic changes ...